nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP2A6—lung cancer	0.187	0.482	CbGaD
Dapagliflozin—CYP1A1—lung cancer	0.131	0.338	CbGaD
Dapagliflozin—ABCB1—lung cancer	0.0695	0.18	CbGaD
Dapagliflozin—UGT1A9—Irinotecan—lung cancer	0.042	0.121	CbGbCtD
Dapagliflozin—CYP1A1—Gefitinib—lung cancer	0.0327	0.0942	CbGbCtD
Dapagliflozin—CYP1A1—Erlotinib—lung cancer	0.0193	0.0557	CbGbCtD
Dapagliflozin—ABCB1—Topotecan—lung cancer	0.014	0.0402	CbGbCtD
Dapagliflozin—CYP2C9—Gefitinib—lung cancer	0.0132	0.0379	CbGbCtD
Dapagliflozin—ABCB1—Gefitinib—lung cancer	0.0128	0.0368	CbGbCtD
Dapagliflozin—CYP2C9—Teniposide—lung cancer	0.0128	0.0368	CbGbCtD
Dapagliflozin—UGT2B4—pericardium—lung cancer	0.0125	0.341	CbGeAlD
Dapagliflozin—CYP2D6—Gefitinib—lung cancer	0.012	0.0347	CbGbCtD
Dapagliflozin—ABCB1—Vinorelbine—lung cancer	0.00983	0.0284	CbGbCtD
Dapagliflozin—CYP2D6—Vinorelbine—lung cancer	0.00926	0.0267	CbGbCtD
Dapagliflozin—CYP1A2—Erlotinib—lung cancer	0.00863	0.0249	CbGbCtD
Dapagliflozin—CYP3A4—Topotecan—lung cancer	0.00836	0.0241	CbGbCtD
Dapagliflozin—ABCB1—Crizotinib—lung cancer	0.00782	0.0226	CbGbCtD
Dapagliflozin—CYP3A4—Gefitinib—lung cancer	0.00765	0.0221	CbGbCtD
Dapagliflozin—ABCB1—Gemcitabine—lung cancer	0.00765	0.022	CbGbCtD
Dapagliflozin—ABCB1—Erlotinib—lung cancer	0.00755	0.0218	CbGbCtD
Dapagliflozin—CYP3A4—Teniposide—lung cancer	0.00742	0.0214	CbGbCtD
Dapagliflozin—CYP2C9—Paclitaxel—lung cancer	0.00712	0.0205	CbGbCtD
Dapagliflozin—CYP2D6—Erlotinib—lung cancer	0.00711	0.0205	CbGbCtD
Dapagliflozin—ABCB1—Paclitaxel—lung cancer	0.00691	0.0199	CbGbCtD
Dapagliflozin—ABCB1—Irinotecan—lung cancer	0.00682	0.0197	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—lung cancer	0.00624	0.018	CbGbCtD
Dapagliflozin—ABCB1—Vinblastine—lung cancer	0.00606	0.0175	CbGbCtD
Dapagliflozin—CYP3A4—Vinorelbine—lung cancer	0.00589	0.017	CbGbCtD
Dapagliflozin—CYP2C9—Cisplatin—lung cancer	0.00572	0.0165	CbGbCtD
Dapagliflozin—CYP2D6—Vinblastine—lung cancer	0.00571	0.0165	CbGbCtD
Dapagliflozin—ABCB1—Cisplatin—lung cancer	0.00556	0.016	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—lung cancer	0.00546	0.0157	CbGbCtD
Dapagliflozin—ABCB1—Docetaxel—lung cancer	0.00499	0.0144	CbGbCtD
Dapagliflozin—CYP3A4—Crizotinib—lung cancer	0.00469	0.0135	CbGbCtD
Dapagliflozin—CYP3A4—Erlotinib—lung cancer	0.00452	0.013	CbGbCtD
Dapagliflozin—CYP3A4—Paclitaxel—lung cancer	0.00414	0.0119	CbGbCtD
Dapagliflozin—CYP3A4—Irinotecan—lung cancer	0.00408	0.0118	CbGbCtD
Dapagliflozin—SLC5A1—mammary gland—lung cancer	0.00388	0.106	CbGeAlD
Dapagliflozin—ABCB1—Doxorubicin—lung cancer	0.00372	0.0107	CbGbCtD
Dapagliflozin—CYP3A4—Vinblastine—lung cancer	0.00363	0.0105	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—lung cancer	0.00361	0.0104	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—lung cancer	0.00351	0.0101	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—lung cancer	0.00327	0.00943	CbGbCtD
Dapagliflozin—CYP3A4—Docetaxel—lung cancer	0.00299	0.00863	CbGbCtD
Dapagliflozin—SLC5A1—respiratory system—lung cancer	0.00259	0.0705	CbGeAlD
Dapagliflozin—CYP3A4—Doxorubicin—lung cancer	0.00223	0.00643	CbGbCtD
Dapagliflozin—SLC5A1—epithelium—lung cancer	0.00216	0.0589	CbGeAlD
Dapagliflozin—SLC5A1—bronchus—lung cancer	0.00213	0.058	CbGeAlD
Dapagliflozin—SLC5A1—trachea—lung cancer	0.00191	0.0521	CbGeAlD
Dapagliflozin—SLC5A1—cardiac atrium—lung cancer	0.0018	0.0489	CbGeAlD
Dapagliflozin—UGT2B4—cardiac atrium—lung cancer	0.00165	0.0451	CbGeAlD
Dapagliflozin—SLC5A1—lung—lung cancer	0.00137	0.0374	CbGeAlD
Dapagliflozin—UGT2B4—lung—lung cancer	0.00127	0.0345	CbGeAlD
Dapagliflozin—Canagliflozin—ALB—lung cancer	0.000964	0.512	CrCbGaD
Dapagliflozin—Canagliflozin—ABCB1—lung cancer	0.00092	0.488	CrCbGaD
Dapagliflozin—CYP2C9—mammary gland—lung cancer	0.000704	0.0192	CbGeAlD
Dapagliflozin—CYP2A6—lung—lung cancer	0.000499	0.0136	CbGeAlD
Dapagliflozin—CYP1A2—respiratory system—lung cancer	0.000494	0.0135	CbGeAlD
Dapagliflozin—CYP1A1—respiratory system—lung cancer	0.000487	0.0133	CbGeAlD
Dapagliflozin—CYP1A1—epithelium—lung cancer	0.000407	0.0111	CbGeAlD
Dapagliflozin—CYP1A1—bronchus—lung cancer	0.000401	0.0109	CbGeAlD
Dapagliflozin—CYP1A1—trachea—lung cancer	0.00036	0.00982	CbGeAlD
Dapagliflozin—CYP1A1—cardiac atrium—lung cancer	0.000338	0.00922	CbGeAlD
Dapagliflozin—CYP1A2—lung—lung cancer	0.000262	0.00715	CbGeAlD
Dapagliflozin—CYP1A1—lung—lung cancer	0.000259	0.00705	CbGeAlD
Dapagliflozin—ABCB1—respiratory system—lung cancer	0.000253	0.0069	CbGeAlD
Dapagliflozin—ABCB1—epithelium—lung cancer	0.000212	0.00577	CbGeAlD
Dapagliflozin—ABCB1—trachea—lung cancer	0.000187	0.0051	CbGeAlD
Dapagliflozin—CYP1A1—lymph node—lung cancer	0.000177	0.00482	CbGeAlD
Dapagliflozin—Infestation NOS—Paclitaxel—lung cancer	0.000162	0.00149	CcSEcCtD
Dapagliflozin—Infestation—Paclitaxel—lung cancer	0.000162	0.00149	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—lung cancer	0.000162	0.00149	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—lung cancer	0.00016	0.00147	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—lung cancer	0.00016	0.00147	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cisplatin—lung cancer	0.00016	0.00147	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Paclitaxel—lung cancer	0.000159	0.00147	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Docetaxel—lung cancer	0.000159	0.00146	CcSEcCtD
Dapagliflozin—Renal failure—Paclitaxel—lung cancer	0.000159	0.00146	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.000159	0.00146	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cisplatin—lung cancer	0.000159	0.00146	CcSEcCtD
Dapagliflozin—Myocardial infarction—Paclitaxel—lung cancer	0.000158	0.00146	CcSEcCtD
Dapagliflozin—Urethral disorder—Cisplatin—lung cancer	0.000158	0.00146	CcSEcCtD
Dapagliflozin—Discomfort—Vinorelbine—lung cancer	0.000158	0.00145	CcSEcCtD
Dapagliflozin—Constipation—Vinblastine—lung cancer	0.000158	0.00145	CcSEcCtD
Dapagliflozin—Urinary tract infection—Paclitaxel—lung cancer	0.000157	0.00145	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Topotecan—lung cancer	0.000155	0.00142	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vinorelbine—lung cancer	0.000153	0.00141	CcSEcCtD
Dapagliflozin—Constipation—Topotecan—lung cancer	0.000153	0.00141	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Erlotinib—lung cancer	0.000153	0.00141	CcSEcCtD
Dapagliflozin—Rash—Teniposide—lung cancer	0.000152	0.0014	CcSEcCtD
Dapagliflozin—Dermatitis—Teniposide—lung cancer	0.000152	0.0014	CcSEcCtD
Dapagliflozin—Infection—Vinorelbine—lung cancer	0.000152	0.0014	CcSEcCtD
Dapagliflozin—Constipation—Erlotinib—lung cancer	0.000152	0.0014	CcSEcCtD
Dapagliflozin—Headache—Teniposide—lung cancer	0.000151	0.00139	CcSEcCtD
Dapagliflozin—Back pain—Irinotecan—lung cancer	0.00015	0.00138	CcSEcCtD
Dapagliflozin—Angina pectoris—Docetaxel—lung cancer	0.00015	0.00138	CcSEcCtD
Dapagliflozin—Skin disorder—Vinorelbine—lung cancer	0.000149	0.00137	CcSEcCtD
Dapagliflozin—ABCB1—bone marrow—lung cancer	0.000148	0.00404	CbGeAlD
Dapagliflozin—Diabetes mellitus—Methotrexate—lung cancer	0.000147	0.00136	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—lung cancer	0.000146	0.00135	CcSEcCtD
Dapagliflozin—Back pain—Gemcitabine—lung cancer	0.000146	0.00134	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—lung cancer	0.000146	0.00134	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—lung cancer	0.000145	0.00134	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—lung cancer	0.000144	0.00133	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—lung cancer	0.000144	0.00133	CcSEcCtD
Dapagliflozin—Nausea—Teniposide—lung cancer	0.000144	0.00132	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Paclitaxel—lung cancer	0.000143	0.00132	CcSEcCtD
Dapagliflozin—Hypotension—Vinorelbine—lung cancer	0.000143	0.00132	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Paclitaxel—lung cancer	0.000143	0.00131	CcSEcCtD
Dapagliflozin—Urticaria—Topotecan—lung cancer	0.000142	0.00131	CcSEcCtD
Dapagliflozin—Urethral disorder—Paclitaxel—lung cancer	0.000142	0.00131	CcSEcCtD
Dapagliflozin—Body temperature increased—Topotecan—lung cancer	0.000142	0.0013	CcSEcCtD
Dapagliflozin—Malnutrition—Cisplatin—lung cancer	0.000141	0.00129	CcSEcCtD
Dapagliflozin—Body temperature increased—Erlotinib—lung cancer	0.00014	0.00129	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—lung cancer	0.000138	0.00127	CcSEcCtD
Dapagliflozin—Infestation NOS—Docetaxel—lung cancer	0.000137	0.00126	CcSEcCtD
Dapagliflozin—Infestation—Docetaxel—lung cancer	0.000137	0.00126	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vinblastine—lung cancer	0.000136	0.00125	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Docetaxel—lung cancer	0.000135	0.00124	CcSEcCtD
Dapagliflozin—Renal failure—Docetaxel—lung cancer	0.000135	0.00124	CcSEcCtD
Dapagliflozin—ABCB1—lung—lung cancer	0.000134	0.00366	CbGeAlD
Dapagliflozin—Myocardial infarction—Docetaxel—lung cancer	0.000134	0.00124	CcSEcCtD
Dapagliflozin—Hypertension—Irinotecan—lung cancer	0.000134	0.00123	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000132	0.00122	CcSEcCtD
Dapagliflozin—Hypersensitivity—Topotecan—lung cancer	0.000132	0.00122	CcSEcCtD
Dapagliflozin—Constipation—Vinorelbine—lung cancer	0.000131	0.00121	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—lung cancer	0.000131	0.0012	CcSEcCtD
Dapagliflozin—Discomfort—Irinotecan—lung cancer	0.00013	0.0012	CcSEcCtD
Dapagliflozin—Hypertension—Gemcitabine—lung cancer	0.00013	0.0012	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—lung cancer	0.000129	0.00119	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—lung cancer	0.000128	0.00117	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000128	0.00117	CcSEcCtD
Dapagliflozin—Discomfort—Gemcitabine—lung cancer	0.000127	0.00117	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Irinotecan—lung cancer	0.000126	0.00116	CcSEcCtD
Dapagliflozin—Oedema—Irinotecan—lung cancer	0.000126	0.00116	CcSEcCtD
Dapagliflozin—Malnutrition—Paclitaxel—lung cancer	0.000126	0.00116	CcSEcCtD
Dapagliflozin—Infection—Irinotecan—lung cancer	0.000126	0.00116	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—lung cancer	0.000125	0.00115	CcSEcCtD
Dapagliflozin—Oedema—Gemcitabine—lung cancer	0.000123	0.00113	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Gemcitabine—lung cancer	0.000123	0.00113	CcSEcCtD
Dapagliflozin—Infection—Gemcitabine—lung cancer	0.000122	0.00113	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Irinotecan—lung cancer	0.000122	0.00112	CcSEcCtD
Dapagliflozin—Back pain—Paclitaxel—lung cancer	0.000122	0.00112	CcSEcCtD
Dapagliflozin—Dizziness—Vinblastine—lung cancer	0.000122	0.00112	CcSEcCtD
Dapagliflozin—Urticaria—Vinorelbine—lung cancer	0.000122	0.00112	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Docetaxel—lung cancer	0.000121	0.00112	CcSEcCtD
Dapagliflozin—Body temperature increased—Vinorelbine—lung cancer	0.000121	0.00112	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Docetaxel—lung cancer	0.000121	0.00111	CcSEcCtD
Dapagliflozin—Urethral disorder—Docetaxel—lung cancer	0.000121	0.00111	CcSEcCtD
Dapagliflozin—Skin disorder—Gemcitabine—lung cancer	0.00012	0.0011	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Gemcitabine—lung cancer	0.000119	0.0011	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000119	0.00109	CcSEcCtD
Dapagliflozin—Dizziness—Topotecan—lung cancer	0.000118	0.00109	CcSEcCtD
Dapagliflozin—Discomfort—Cisplatin—lung cancer	0.000118	0.00109	CcSEcCtD
Dapagliflozin—Hypotension—Irinotecan—lung cancer	0.000118	0.00109	CcSEcCtD
Dapagliflozin—Dizziness—Erlotinib—lung cancer	0.000117	0.00108	CcSEcCtD
Dapagliflozin—Headache—Vinblastine—lung cancer	0.000116	0.00106	CcSEcCtD
Dapagliflozin—Angioedema—Paclitaxel—lung cancer	0.000115	0.00106	CcSEcCtD
Dapagliflozin—Hypotension—Gemcitabine—lung cancer	0.000115	0.00106	CcSEcCtD
Dapagliflozin—Oedema—Cisplatin—lung cancer	0.000115	0.00106	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Cisplatin—lung cancer	0.000115	0.00106	CcSEcCtD
Dapagliflozin—Infection—Cisplatin—lung cancer	0.000114	0.00105	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—lung cancer	0.000114	0.00105	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—lung cancer	0.000113	0.00104	CcSEcCtD
Dapagliflozin—Rash—Topotecan—lung cancer	0.000113	0.00104	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vinorelbine—lung cancer	0.000113	0.00104	CcSEcCtD
Dapagliflozin—Dermatitis—Topotecan—lung cancer	0.000113	0.00104	CcSEcCtD
Dapagliflozin—Headache—Topotecan—lung cancer	0.000112	0.00103	CcSEcCtD
Dapagliflozin—Rash—Erlotinib—lung cancer	0.000112	0.00103	CcSEcCtD
Dapagliflozin—Dermatitis—Erlotinib—lung cancer	0.000112	0.00103	CcSEcCtD
Dapagliflozin—Skin disorder—Cisplatin—lung cancer	0.000111	0.00103	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—lung cancer	0.000111	0.00103	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—lung cancer	0.000111	0.00102	CcSEcCtD
Dapagliflozin—Headache—Erlotinib—lung cancer	0.000111	0.00102	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—lung cancer	0.000111	0.00102	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cisplatin—lung cancer	0.000111	0.00102	CcSEcCtD
Dapagliflozin—Nausea—Vinblastine—lung cancer	0.00011	0.00101	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Irinotecan—lung cancer	0.000109	0.001	CcSEcCtD
Dapagliflozin—Hypertension—Paclitaxel—lung cancer	0.000109	0.001	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000109	0.001	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—lung cancer	0.000108	0.000998	CcSEcCtD
Dapagliflozin—Constipation—Irinotecan—lung cancer	0.000108	0.000995	CcSEcCtD
Dapagliflozin—Hypotension—Cisplatin—lung cancer	0.000107	0.000987	CcSEcCtD
Dapagliflozin—Malnutrition—Docetaxel—lung cancer	0.000107	0.000986	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000107	0.000983	CcSEcCtD
Dapagliflozin—Nausea—Topotecan—lung cancer	0.000106	0.00098	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000106	0.000979	CcSEcCtD
Dapagliflozin—Discomfort—Paclitaxel—lung cancer	0.000106	0.000978	CcSEcCtD
Dapagliflozin—Constipation—Gemcitabine—lung cancer	0.000105	0.000969	CcSEcCtD
Dapagliflozin—Nausea—Erlotinib—lung cancer	0.000105	0.000969	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—lung cancer	0.000105	0.000968	CcSEcCtD
Dapagliflozin—Infection—Etoposide—lung cancer	0.000104	0.000962	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—lung cancer	0.000104	0.000957	CcSEcCtD
Dapagliflozin—Back pain—Docetaxel—lung cancer	0.000104	0.000953	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—lung cancer	0.000104	0.000953	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—lung cancer	0.000103	0.00095	CcSEcCtD
Dapagliflozin—Oedema—Paclitaxel—lung cancer	0.000103	0.000949	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Paclitaxel—lung cancer	0.000103	0.000949	CcSEcCtD
Dapagliflozin—Infection—Paclitaxel—lung cancer	0.000102	0.000943	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—lung cancer	0.000102	0.00094	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—lung cancer	0.000102	0.000936	CcSEcCtD
Dapagliflozin—Dizziness—Vinorelbine—lung cancer	0.000101	0.000933	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—lung cancer	0.000101	0.000933	CcSEcCtD
Dapagliflozin—Skin disorder—Paclitaxel—lung cancer	0.0001	0.000922	CcSEcCtD
Dapagliflozin—Body temperature increased—Irinotecan—lung cancer	9.99e-05	0.00092	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Paclitaxel—lung cancer	9.97e-05	0.000917	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—lung cancer	9.92e-05	0.000913	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cisplatin—lung cancer	9.91e-05	0.000912	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—lung cancer	9.88e-05	0.000909	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—lung cancer	9.88e-05	0.000909	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—lung cancer	9.83e-05	0.000904	CcSEcCtD
Dapagliflozin—Body temperature increased—Gemcitabine—lung cancer	9.73e-05	0.000896	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—lung cancer	9.71e-05	0.000894	CcSEcCtD
Dapagliflozin—Rash—Vinorelbine—lung cancer	9.66e-05	0.00089	CcSEcCtD
Dapagliflozin—Dermatitis—Vinorelbine—lung cancer	9.66e-05	0.000889	CcSEcCtD
Dapagliflozin—Hypotension—Paclitaxel—lung cancer	9.63e-05	0.000887	CcSEcCtD
Dapagliflozin—Headache—Vinorelbine—lung cancer	9.6e-05	0.000884	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—lung cancer	9.59e-05	0.000883	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—lung cancer	9.34e-05	0.00086	CcSEcCtD
Dapagliflozin—Hypersensitivity—Irinotecan—lung cancer	9.31e-05	0.000857	CcSEcCtD
Dapagliflozin—Hypertension—Docetaxel—lung cancer	9.24e-05	0.000851	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—lung cancer	9.19e-05	0.00251	CbGeAlD
Dapagliflozin—Nausea—Vinorelbine—lung cancer	9.1e-05	0.000838	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—lung cancer	9.08e-05	0.000836	CcSEcCtD
Dapagliflozin—Body temperature increased—Cisplatin—lung cancer	9.07e-05	0.000835	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	9.05e-05	0.000833	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—lung cancer	8.99e-05	0.000828	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—lung cancer	8.97e-05	0.000825	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Paclitaxel—lung cancer	8.9e-05	0.000819	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—lung cancer	8.86e-05	0.000815	CcSEcCtD
Dapagliflozin—Constipation—Paclitaxel—lung cancer	8.82e-05	0.000812	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—lung cancer	8.75e-05	0.000806	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Docetaxel—lung cancer	8.74e-05	0.000804	CcSEcCtD
Dapagliflozin—Oedema—Docetaxel—lung cancer	8.74e-05	0.000804	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—lung cancer	8.69e-05	0.0008	CcSEcCtD
Dapagliflozin—Infection—Docetaxel—lung cancer	8.68e-05	0.000799	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—lung cancer	8.55e-05	0.000787	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—lung cancer	8.55e-05	0.000787	CcSEcCtD
Dapagliflozin—Skin disorder—Docetaxel—lung cancer	8.49e-05	0.000781	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cisplatin—lung cancer	8.46e-05	0.000778	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—lung cancer	8.41e-05	0.000774	CcSEcCtD
Dapagliflozin—Dizziness—Irinotecan—lung cancer	8.36e-05	0.000769	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—lung cancer	8.35e-05	0.000769	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—lung cancer	8.31e-05	0.000765	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—lung cancer	8.31e-05	0.000765	CcSEcCtD
Dapagliflozin—Urticaria—Paclitaxel—lung cancer	8.19e-05	0.000754	CcSEcCtD
Dapagliflozin—Hypotension—Docetaxel—lung cancer	8.17e-05	0.000752	CcSEcCtD
Dapagliflozin—Body temperature increased—Paclitaxel—lung cancer	8.15e-05	0.00075	CcSEcCtD
Dapagliflozin—Rash—Irinotecan—lung cancer	7.97e-05	0.000734	CcSEcCtD
Dapagliflozin—Dermatitis—Irinotecan—lung cancer	7.96e-05	0.000733	CcSEcCtD
Dapagliflozin—Headache—Irinotecan—lung cancer	7.92e-05	0.000729	CcSEcCtD
Dapagliflozin—Rash—Gemcitabine—lung cancer	7.76e-05	0.000715	CcSEcCtD
Dapagliflozin—Dermatitis—Gemcitabine—lung cancer	7.76e-05	0.000714	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—lung cancer	7.75e-05	0.000713	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—lung cancer	7.72e-05	0.00071	CcSEcCtD
Dapagliflozin—Headache—Gemcitabine—lung cancer	7.71e-05	0.00071	CcSEcCtD
Dapagliflozin—Hypersensitivity—Paclitaxel—lung cancer	7.6e-05	0.000699	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—lung cancer	7.58e-05	0.000698	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Docetaxel—lung cancer	7.54e-05	0.000694	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—lung cancer	7.54e-05	0.000694	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—lung cancer	7.52e-05	0.000693	CcSEcCtD
Dapagliflozin—Nausea—Irinotecan—lung cancer	7.51e-05	0.000691	CcSEcCtD
Dapagliflozin—Constipation—Docetaxel—lung cancer	7.47e-05	0.000688	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—lung cancer	7.46e-05	0.000687	CcSEcCtD
Dapagliflozin—Nausea—Gemcitabine—lung cancer	7.31e-05	0.000673	CcSEcCtD
Dapagliflozin—Rash—Cisplatin—lung cancer	7.24e-05	0.000666	CcSEcCtD
Dapagliflozin—Dermatitis—Cisplatin—lung cancer	7.23e-05	0.000666	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—lung cancer	6.95e-05	0.00064	CcSEcCtD
Dapagliflozin—Body temperature increased—Docetaxel—lung cancer	6.91e-05	0.000636	CcSEcCtD
Dapagliflozin—Dizziness—Paclitaxel—lung cancer	6.82e-05	0.000628	CcSEcCtD
Dapagliflozin—Nausea—Cisplatin—lung cancer	6.82e-05	0.000628	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—lung cancer	6.68e-05	0.000615	CcSEcCtD
Dapagliflozin—Rash—Etoposide—lung cancer	6.63e-05	0.00061	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—lung cancer	6.62e-05	0.00061	CcSEcCtD
Dapagliflozin—Headache—Etoposide—lung cancer	6.59e-05	0.000606	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	6.52e-05	0.000601	CcSEcCtD
Dapagliflozin—Rash—Paclitaxel—lung cancer	6.5e-05	0.000598	CcSEcCtD
Dapagliflozin—Dermatitis—Paclitaxel—lung cancer	6.49e-05	0.000598	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—lung cancer	6.49e-05	0.000598	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—lung cancer	6.46e-05	0.000595	CcSEcCtD
Dapagliflozin—Headache—Paclitaxel—lung cancer	6.46e-05	0.000594	CcSEcCtD
Dapagliflozin—Hypersensitivity—Docetaxel—lung cancer	6.44e-05	0.000593	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—lung cancer	6.3e-05	0.00058	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—lung cancer	6.26e-05	0.000576	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—lung cancer	6.25e-05	0.000575	CcSEcCtD
Dapagliflozin—Nausea—Paclitaxel—lung cancer	6.12e-05	0.000564	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—lung cancer	6.12e-05	0.000563	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—lung cancer	6.09e-05	0.00056	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—lung cancer	5.89e-05	0.000542	CcSEcCtD
Dapagliflozin—Dizziness—Docetaxel—lung cancer	5.78e-05	0.000532	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—lung cancer	5.77e-05	0.000531	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	5.65e-05	0.00052	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—lung cancer	5.62e-05	0.000517	CcSEcCtD
Dapagliflozin—Rash—Docetaxel—lung cancer	5.51e-05	0.000507	CcSEcCtD
Dapagliflozin—Dermatitis—Docetaxel—lung cancer	5.5e-05	0.000507	CcSEcCtD
Dapagliflozin—Headache—Docetaxel—lung cancer	5.47e-05	0.000504	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—lung cancer	5.45e-05	0.000502	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—lung cancer	5.45e-05	0.000502	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—lung cancer	5.44e-05	0.000501	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—lung cancer	5.42e-05	0.000499	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—lung cancer	5.3e-05	0.000488	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—lung cancer	5.27e-05	0.000485	CcSEcCtD
Dapagliflozin—Nausea—Docetaxel—lung cancer	5.19e-05	0.000478	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—lung cancer	5.1e-05	0.000469	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—lung cancer	5e-05	0.000461	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—lung cancer	4.98e-05	0.000458	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—lung cancer	4.71e-05	0.000433	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—lung cancer	4.66e-05	0.000429	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—lung cancer	4.64e-05	0.000427	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—lung cancer	4.33e-05	0.000399	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—lung cancer	4.31e-05	0.000397	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—lung cancer	4.16e-05	0.000383	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—lung cancer	4.02e-05	0.00037	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—lung cancer	3.97e-05	0.000366	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—lung cancer	3.97e-05	0.000365	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—lung cancer	3.95e-05	0.000363	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—lung cancer	3.74e-05	0.000344	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—lung cancer	3.61e-05	0.000332	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—lung cancer	3.44e-05	0.000317	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—lung cancer	3.44e-05	0.000316	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—lung cancer	3.42e-05	0.000314	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—lung cancer	3.24e-05	0.000298	CcSEcCtD
Dapagliflozin—CYP1A2—Metabolism—ABCC3—lung cancer	4.08e-06	3.43e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SDC4—lung cancer	4.07e-06	3.42e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPP2R1B—lung cancer	4.06e-06	3.42e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.04e-06	3.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOA3—lung cancer	4.04e-06	3.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1A1—lung cancer	4.02e-06	3.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOA3—lung cancer	4e-06	3.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4e-06	3.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ERCC2—lung cancer	3.99e-06	3.36e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTT1—lung cancer	3.97e-06	3.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKR1C1—lung cancer	3.95e-06	3.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	3.93e-06	3.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCG2—lung cancer	3.93e-06	3.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADCY1—lung cancer	3.93e-06	3.3e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GCLC—lung cancer	3.92e-06	3.3e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2A6—lung cancer	3.92e-06	3.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADCY1—lung cancer	3.89e-06	3.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCG2—lung cancer	3.89e-06	3.27e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—POMC—lung cancer	3.89e-06	3.27e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CB—lung cancer	3.86e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HPGDS—lung cancer	3.85e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO2—lung cancer	3.85e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	3.85e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—UGT1A1—lung cancer	3.84e-06	3.23e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPP2R1B—lung cancer	3.83e-06	3.22e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—lung cancer	3.82e-06	3.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO2—lung cancer	3.82e-06	3.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HPGDS—lung cancer	3.82e-06	3.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPP2R1B—lung cancer	3.8e-06	3.19e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CREBBP—lung cancer	3.79e-06	3.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.75e-06	3.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTT1—lung cancer	3.74e-06	3.14e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—STK11—lung cancer	3.72e-06	3.13e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO1—lung cancer	3.72e-06	3.12e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	3.71e-06	3.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RRM1—lung cancer	3.71e-06	3.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA3—lung cancer	3.71e-06	3.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTT1—lung cancer	3.7e-06	3.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GNG11—lung cancer	3.7e-06	3.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2A6—lung cancer	3.69e-06	3.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GCLC—lung cancer	3.69e-06	3.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	3.68e-06	3.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GCLC—lung cancer	3.66e-06	3.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2A6—lung cancer	3.66e-06	3.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.65e-06	3.07e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CD—lung cancer	3.59e-06	3.02e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALB—lung cancer	3.55e-06	2.98e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALDOA—lung cancer	3.52e-06	2.96e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO1—lung cancer	3.5e-06	2.94e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.49e-06	2.94e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—B4GALT5—lung cancer	3.48e-06	2.93e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	3.48e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO1—lung cancer	3.47e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.46e-06	2.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOA1—lung cancer	3.45e-06	2.9e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—lung cancer	3.44e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOA3—lung cancer	3.42e-06	2.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.41e-06	2.87e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA4—lung cancer	3.39e-06	2.85e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	3.36e-06	2.83e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAT—lung cancer	3.35e-06	2.82e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2E1—lung cancer	3.33e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—lung cancer	3.33e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.33e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADCY1—lung cancer	3.33e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCG2—lung cancer	3.33e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA2—lung cancer	3.3e-06	2.78e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NQO1—lung cancer	3.3e-06	2.77e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO2—lung cancer	3.26e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGDS—lung cancer	3.26e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—lung cancer	3.26e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPP2R1B—lung cancer	3.24e-06	2.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.2e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—lung cancer	3.2e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA1—lung cancer	3.19e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—lung cancer	3.18e-06	2.67e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—lung cancer	3.17e-06	2.66e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—lung cancer	3.16e-06	2.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—lung cancer	3.15e-06	2.65e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCC3—lung cancer	3.15e-06	2.65e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	3.14e-06	2.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2E1—lung cancer	3.14e-06	2.64e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—lung cancer	3.13e-06	2.63e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GCLC—lung cancer	3.13e-06	2.63e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2A6—lung cancer	3.13e-06	2.63e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.12e-06	2.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2E1—lung cancer	3.11e-06	2.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NQO1—lung cancer	3.11e-06	2.61e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—lung cancer	3.1e-06	2.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NQO1—lung cancer	3.08e-06	2.59e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKR1C1—lung cancer	3.05e-06	2.57e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.01e-06	2.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—POMC—lung cancer	3e-06	2.52e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.99e-06	2.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ERCC2—lung cancer	2.97e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—STK11—lung cancer	2.97e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO1—lung cancer	2.97e-06	2.49e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—UGT1A1—lung cancer	2.96e-06	2.49e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.96e-06	2.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CREBBP—lung cancer	2.92e-06	2.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.92e-06	2.45e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GNG11—lung cancer	2.86e-06	2.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—STK11—lung cancer	2.8e-06	2.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—STK11—lung cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—lung cancer	2.77e-06	2.33e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—lung cancer	2.75e-06	2.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—lung cancer	2.74e-06	2.3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDOA—lung cancer	2.72e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—lung cancer	2.71e-06	2.28e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAT—lung cancer	2.67e-06	2.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2E1—lung cancer	2.66e-06	2.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA3—lung cancer	2.64e-06	2.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NQO1—lung cancer	2.63e-06	2.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.61e-06	2.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—lung cancer	2.59e-06	2.18e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—lung cancer	2.58e-06	2.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.58e-06	2.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOA1—lung cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADCY1—lung cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCG2—lung cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—lung cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—lung cancer	2.56e-06	2.15e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.55e-06	2.15e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—lung cancer	2.53e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAT—lung cancer	2.52e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO2—lung cancer	2.52e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGDS—lung cancer	2.52e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.5e-06	2.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAT—lung cancer	2.5e-06	2.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.48e-06	2.09e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.46e-06	2.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—lung cancer	2.45e-06	2.06e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—lung cancer	2.44e-06	2.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—lung cancer	2.43e-06	2.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—lung cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2A6—lung cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GCLC—lung cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—lung cancer	2.41e-06	2.02e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A1—lung cancer	2.39e-06	2.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—lung cancer	2.39e-06	2.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—lung cancer	2.39e-06	2.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—lung cancer	2.38e-06	2e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ERCC2—lung cancer	2.37e-06	2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—STK11—lung cancer	2.37e-06	1.99e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—lung cancer	2.36e-06	1.98e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—lung cancer	2.35e-06	1.98e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—lung cancer	2.35e-06	1.97e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO1—lung cancer	2.29e-06	1.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A1—lung cancer	2.26e-06	1.9e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ERCC2—lung cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A1—lung cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—POMC—lung cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.23e-06	1.87e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ERCC2—lung cancer	2.22e-06	1.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—lung cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CREBBP—lung cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAT—lung cancer	2.14e-06	1.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.12e-06	1.78e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—lung cancer	2.09e-06	1.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—lung cancer	2.08e-06	1.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—lung cancer	2.06e-06	1.74e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOA1—lung cancer	2.05e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2E1—lung cancer	2.05e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—lung cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—lung cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NQO1—lung cancer	2.03e-06	1.71e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—lung cancer	2.02e-06	1.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—lung cancer	1.99e-06	1.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOA1—lung cancer	1.94e-06	1.63e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—lung cancer	1.92e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOA1—lung cancer	1.92e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1A1—lung cancer	1.91e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—lung cancer	1.91e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ERCC2—lung cancer	1.9e-06	1.59e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—lung cancer	1.88e-06	1.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.84e-06	1.55e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—STK11—lung cancer	1.83e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—lung cancer	1.8e-06	1.51e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—POMC—lung cancer	1.79e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—lung cancer	1.78e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—lung cancer	1.77e-06	1.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—lung cancer	1.75e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CREBBP—lung cancer	1.74e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—lung cancer	1.69e-06	1.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—POMC—lung cancer	1.68e-06	1.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—POMC—lung cancer	1.67e-06	1.4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—lung cancer	1.65e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAT—lung cancer	1.65e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOA1—lung cancer	1.64e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CREBBP—lung cancer	1.64e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—lung cancer	1.63e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CREBBP—lung cancer	1.62e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—lung cancer	1.6e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—lung cancer	1.57e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.57e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—lung cancer	1.56e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—lung cancer	1.56e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—lung cancer	1.55e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—lung cancer	1.55e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—lung cancer	1.54e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—lung cancer	1.53e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—lung cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—lung cancer	1.5e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—lung cancer	1.48e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A1—lung cancer	1.48e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—lung cancer	1.47e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ERCC2—lung cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—lung cancer	1.44e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—POMC—lung cancer	1.43e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—lung cancer	1.42e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CREBBP—lung cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—lung cancer	1.35e-06	1.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—lung cancer	1.34e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—lung cancer	1.34e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—lung cancer	1.33e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—lung cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—lung cancer	1.3e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOA1—lung cancer	1.27e-06	1.06e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—lung cancer	1.24e-06	1.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—lung cancer	1.2e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—lung cancer	1.18e-06	9.96e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—lung cancer	1.17e-06	9.84e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—lung cancer	1.16e-06	9.75e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—lung cancer	1.16e-06	9.71e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—lung cancer	1.15e-06	9.65e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—lung cancer	1.14e-06	9.56e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—lung cancer	1.12e-06	9.38e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—lung cancer	1.11e-06	9.3e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—POMC—lung cancer	1.1e-06	9.25e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—lung cancer	1.1e-06	9.22e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CREBBP—lung cancer	1.07e-06	9.01e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—lung cancer	1.02e-06	8.54e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—lung cancer	1e-06	8.43e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—lung cancer	9.91e-07	8.33e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—lung cancer	9.45e-07	7.95e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—lung cancer	8.96e-07	7.53e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—lung cancer	8.85e-07	7.44e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—lung cancer	8.77e-07	7.38e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—lung cancer	8.76e-07	7.37e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—lung cancer	8.26e-07	6.94e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—lung cancer	8.18e-07	6.88e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—lung cancer	7.65e-07	6.43e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—lung cancer	7.3e-07	6.13e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—lung cancer	7.16e-07	6.02e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—lung cancer	6.99e-07	5.88e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—lung cancer	6.74e-07	5.67e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—lung cancer	6.69e-07	5.62e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—lung cancer	5.71e-07	4.8e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—lung cancer	5.4e-07	4.54e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—lung cancer	4.41e-07	3.71e-06	CbGpPWpGaD
